Article Document Academic Article Information Content Entity Journal Article Continuant Continuant Entity Entity Generically Dependent Continuant 2025-06-24T06:20:39 RDF description of Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States - http://repository.healthpartners.com/individual/document-rn35059 <p>In the United States, annual influenza vaccination is recommended for all persons aged � 6 months. Using data from four vaccine effectiveness (VE) networks during the 2023-24 influenza season, interim influenza VE was estimated among patients aged � 6 months with acute respiratory illness-associated medical encounters using a test-negative case-control study design. Among children and adolescents aged 6 months-17 years, VE against influenza-associated outpatient visits ranged from 59% to 67% and against influenza-associated hospitalization ranged from 52% to 61%. Among adults aged � 18 years, VE against influenza-associated outpatient visits ranged from 33% to 49% and against hospitalization from 41% to 44%. VE against influenza A ranged from 46% to 59% for children and adolescents and from 27% to 46% for adults across settings. VE against influenza B ranged from 64% to 89% for pediatric patients in outpatient settings and from 60% to 78% for all adults across settings. These findings demonstrate that the 2023-24 seasonal influenza vaccine is effective at reducing the risk for medically attended influenza virus infection. CDC recommends that all persons aged � 6 months who have not yet been vaccinated this season get vaccinated while influenza circulates locally.<p> 73 Prevention 10.15585/mmwr.mm7308a3 2024-03-14T20:32:48.401-05:00 Influenza Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States MMWR: Morbidity and Mortality Weekly Report Case-Control Studies Influenza Vaccines 8 38068 Pediatrics public 22154 document-rn35059